Overview

Cardiac biomarker diagnostic kits market is poised to reach USD 4.5 billion by 2027 end and achieve a CAGR of over 7% from the forecast period 2020-2027.

Factors such as increasing geriatric population and increasing cases of cardiovascular diseases are increasing the cardiac biomarker diagnostic kits market size. Current clinical trials for identification of novel cardiac biomarkers coupled with increasing fund from public-private organizations for research and development is also expanding the market.

The market is bifurcated into by type, by product, by disease, by type of testing and by region. The troponin I and T segment are expected to show notable cardiac biomarker diagnostic kits market growth owing to its high sensitivity, rapid prediction of outcomes and high specificity. It also offers longer elevation time. All these benefits have resulted in demand for troponin I and T, thus proliferating the market. 

Based on product, reagents and kits are expected to dominate the growth of the market. Increasing cases of cardiovascular diseases and the availability of multiple reagents ad kits is driving the growth of the market. In addition, the continuous launch of reliable, faster and new reagents and kits increasing the cardiac biomarker diagnostic kits size. 

On the basis of the type of testing, point-of-care testing is expected to control the growth of the market. Point-of-care testing offers various benefits such as enhanced user and patient experience, reduced length of stay and better turnaround times. All these benefits have resulted in rising point-of-care testing procedures. Technological advancements have led in much faster, advances and easy to use devices, thus resulting in expansion of the market.

In terms of disease, myocardial infarction segment is expected to control the growth of the market. The increasing number of patients required for the diagnosis of acute myocardial infarction remains the major factor boosting the growth of the market.

In terms of region, North America is the global front runner of the market. The rise in geriatric population coupled with presence of prominent players is bolstering the market in the region. The increasing incidence of cardiovascular disease coupled with rising adoption of point-of-care diagnostic is expected to accelerate the growth of the market in the region. 

Prominent players of the market are bioMerieux SA, Guangzhou Wondfo Biotech Co., Ltd, Danaher Corporation, Siemens AG, Abbott Laboratories, Alere, Inc., LSI Medience Corporation, Randox laboratories, and Ortho Clinical Diagnostics. 

Competitive Landscape:

• Abbott in 2017 acquired Alere. The acquisition helped in bolstering the company's portfolio

Global Cardiac Biomarker Diagnostic Kits Market Segmentation

 By Type 

• Troponin I and T 
• CK-MB 
• Bnp Or Nt-Probnp 
• Myoglobin 
• Hscrp 
• Other Biomarkers 

By Product 

• Reagents and Kits 
• Instruments 
• Chemiluminescence
• Immunofluorescence
• Elisa
• Immunochromatography

By Disease 

• Myocardial Infarction 
• Congestive Heart Failure 

By Type of Testing 

•   Laboratory Testing 
•   Point-Of-Care Testing 

By Region 

• North America
• Europe
• Asia Pacific
• Latin America
• Rest of the World

FutureWise Key Takeaways:

• Growth Prospects
• SWOT Analysis
• Key Trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the global cardiac biomarker diagnostic kits market by type, by product, by disease, by type of testing and by region
•  To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities)
• To forecast and evaluate micro-markets and the overall market 
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and the rest of the world 
• To record, evaluate and analyse competitive landscape mapping- technological advancements, product launches, expansions and mergers 

Table of Contents

1 Introduction

1.1 Objectives of the Study 

1.2 Market Definition 

1.3 Markets Covered 

        1.3.1 Years Considered for the Study

1.4 Currency 

1.5 Limitations 

1.6 Stakeholders 

2 Research Methodology 

2.1 Research Methodology Steps 

2.2 Secondary and Primary Research Methodology 

        2.2.1 Secondary Research

                 2.2.1.1 Key Data From Secondary Sources

        2.2.2 Primary Research

                 2.2.2.1 Breakdown of Primaries

                 2.2.2.2 Key Data From Primary Sources

2.3 Market Size Estimation 

        2.3.1 Research Methodology: Bottom-Up Approach

        2.3.2 Research Methodology: Top-Down Approach

2.4 Market Breakdown and Data Triangulation 

3 Executive Summary 

3.1 Introduction 

3.2 Evolution 

3.3 Current Scenario 

3.4 Future Outlook 

3.5 Conclusion 

4 Premium Insights 

4.1 Global Cardiac Marker Testing Market Overview 

4.2 Geographic Analysis: Cardiac Marker Testing Market, By Technology, 2017 

4.3 Market Size, By Type, 2017 vs 2022 

4.4 Market, By Product, 2017 vs 2022 

4.5 Geographical Snapshot of the Market, 2017 

4.6 Life Cycle Analysis, By Region 

5 Market Overview 

5.1 Introduction 

5.2 Market Dynamics 

        5.2.1 Drivers

                 5.2.1.1 Growing Incidences of Cardiovascular Diseases

                 5.2.1.2 Rapidly Increasing Geriatric Population and the Subsequent Increase in the Burden of Heart Diseases Worldwide

                 5.2.1.3 Growing Funding From Public–Private Organizations for Research on Cardiac Biomarkers

                 5.2.1.4 Ongoing Clinical Trials for Identification of Novel Cardiac Biomarkers

        5.2.2 Restraints

                 5.2.2.1 Technical Problems Related to Sample Collection and Storage

                 5.2.2.2 Issues Related to Regulatory and Reimbursement Systems

        5.2.3 Opportunities

                 5.2.3.1 Point-Of-Care Testing (Poct) With Cardiac Biomarkers

                 5.2.3.2 Emerging Markets to Offer New Growth Avenues for Market Players

6 Industry Insights 

6.1 Introduction 

6.2 Value Chain Analysis 

6.3 Industry Trends 

        6.3.1 Ongoing Research on Novel Cardiac Biomarkers for Cardiovascular Diseases

        6.3.2 Combination of Various Cardiac Biomarkers to Improve Patient Management

        6.3.3 Development of High-Sensitivity Troponin Assays

6.4 Porter’s Five Forces Analysis 

        6.4.1 Threat of New Entrants

        6.4.2 Threat of Substitutes

        6.4.3 Bargaining Power of Suppliers

        6.4.4 Bargaining Power of Buyers

        6.4.5 Intensity of Competitive Rivalry

7 Cardiac Marker Testing Market, By Type 

7.1 Introduction 

7.2 Troponin I and T 

7.3 CK-MB 

7.4 Bnp Or Nt-Probnp 

7.5 Myoglobin 

7.6 Hscrp 

7.7 Other Biomarkers 

8 Cardiac Marker Testing Market, By Product 

8.1 Introduction 

8.2 Reagents and Kits 

8.3 Instruments 

        8.3.1 Chemiluminescence

        8.3.2 Immunofluorescence

        8.3.3 Elisa

        8.3.4 Immunochromatography

9 Cardiac Marker Testing Market, By Disease 

9.1 Introduction 

9.2 Myocardial Infarction 

9.3 Congestive Heart Failure 

10 Cardiac Marker Testing Market, By Type of Testing 

  10.1 Introduction 

  10.2 Laboratory Testing 

  10.3 Point-Of-Care Testing 

11 Cardiac Marker Testing Market, By Region 

  11.1 Introduction 

  11.2 North America 

          11.2.1 U.S.

                     11.2.1.1 Growing Prevalence of Cardiovascular Diseases

                     11.2.1.2 Increasing Public-Private Investments on Cardiac Biomarker Research

                     11.2.1.3 Rising Geriatric & Obese Population

                     11.2.1.4 Nih Support for the Development of Cardiac Biomarkers

          11.2.2 Canada

                     11.2.2.1 Rising Incidence of Cardiovascular Diseases

                     11.2.2.2 Increasing Government Investments

  11.3 Europe 

          11.3.1 Rising Incidence of CVD

          11.3.2 Increasing Number of Conferences and Symposiums

          11.3.3 Rising Partnerships and Collaborations for the Development of Cardiac Biomarkers

          11.3.4 Increasing Government Investments to Develop Novel Cardiac Biomarkers

  11.4 Asia-Pacific 

          11.4.1 Increasing Incidence of CVD

          11.4.2 Increasing Awareness Due to Going Conferences and Initiatives Taken By Market Players

          11.4.3 Government Investments Towards Cardiac Biomarker Research

  11.5 Rest of the World 

12 Competitive Landscape 

  12.1 Introduction 

  12.2 Strategic Overview 

  12.3 Leading Players in the Market 

  12.4 Competitive Situation and Trends 

          12.4.1 Product Launches, Approvals, and Showcases

          12.4.2 Agreements and Partnerships

          12.4.3 Acquisitions

          12.4.4 Other Developments

13 Company Profiles

(Overview, Products and Services, Financials, Strategy & Development)*

  13.1 Introduction 

  13.2 Roche Diagnostics Limited (A Subsidiary of F. Hoffman-LA Roche Ltd.) 

  13.3 Abbott Laboratories 

  13.4 Siemens AG 

  13.5 Danaher Corporation 

  13.6 Biomérieux SA 

  13.7 Alere Inc. 

  13.8 LSI Medience Corporation (A Subsidiary 0f Mitsubishi Chemical Holdings Corporation) 

  13.9 Ortho Clinical Diagnostics (A Subsidiary of the Carlyle Group) 

  13.10 Randox Laboratories Ltd. 

  13.11 Guangzhou Wondfo Biotech Co., Ltd.

Chapter 14 Research Finding and Conclusion 

Chapter 15  Research Methodology 

Chapter 16  Research Data Source

Tables

Figures